Supplementary Information

A CRISPR-Cas9-triggered strand displacement amplification method for ultrasensitive DNA detection

Zhou *et al.*

Supplementary Figure 1. Representative PAGE analysis showing CRISDA cannot initiate amplification of target pTF1 without Cas9. The representative gel analysis illustrating CRISDA fails to produce any amplicon from attomolar target pTF1 in the absence of the Cas9 protein. The arrow indicates the position of theoretic 186 bp amplicon.

Supplementary Figure 2. Representative PAGE analysis showing that CRISDA detects attomolar pTF1 targets in combination with the PNA. The CRISDA reactions proceed at 37 °C for 90 min and the arrows indicate that PNA-invasion is confirmed by altered migration of Cy5-positive species in 6% native PAGE. Although lanes without target pTF1 also reveal Cy5-positive species, they do not interact with Biotin-labeled PNA and thus are not pulled down and interfere with subsequent fluorescence measurements.

Supplementary Figure 3. Representative calibration curve for target pTF1 detection with CRISDA. Cy5 fluorescence intensities from CRISDA combined with PNA invasion-mediated fluorescence measurements are plotted against log of concentration of target pTF1, showing significant correlation between the target concentration and detected fluorescence intensity. The red line is the linear regression fit $(R^2 = 0.993)$.

Supplementary Figure 4. Representative PAGE analysis showing the great temperature tolerance of CRISDA. CRISDA reactions amplifying 250 aM of target pTF1 are conducted at temperature ranging from 25 to 46 °C. Successful amplifications are obtained when CRISDA reactions take place between 28 and 43 °C, indicating large temperature tolerance of CRISDA.

Supplementary Figure 5. Representative PAGE analysis showing the critical function of the 3' overhang in IPprimers. The melting temperature of 3' overhangs must be over 50 °C for successful CRISDA reactions (*: Sequencing verification confirms that it is a product from the primer dimer rather than the targeted amplicon.) CRISDA reactions are carried out at 37 °C for 90 min with 250 aM pTF1 as the target.

Supplementary Figure 6. Schematic of CRISDA-based DNA amplification and detection towards an 877 bp DNA fragment hTF1. DNA fragment hTF1 is derived from Chromosome 9 in the human genome. Two pairs of sgRNAs ($sghTF1-UPSI/DNS1$, and $sghTF1-UPS2/DNS2)$ and IP primers (IP $hTF1-UPS1/DNS1$, and IP $hTF1-UPS2/DNS2)$ are designed to specifically target and amplify a 169 bp (T1) and 203 bp (T2) region in hTF1, respectively. In genomic CRISDA, the same sgRNAs and IP primer pairs are used to amplify the corresponding T1 and T2 regions in the human genomic DNA extracted from HEK293 cells.

Supplementary Figure 7. PAGE analyses showing Cas9 protein is critical in genomic CRISDA amplification reactions. (**a**) CRISDA reactions containing Cas9 successfully amplify T1 (the left graph) and T2 (the right graph) from 67 aM human genomic DNA extracted from HEK293 cells. The arrows indicate successful amplification of the targeted amplicons. (**b**) CRISDA reactions fail to produce any amplicon from human genomic DNA in the absence of Cas9 protein. The arrows indicate the position of theoretic amplicon which is absent from the CRISDA reactions without Cas9.

Supplementary Figure 8. PAGE analysis showing CRISDA is capable of highly sensitive amplification of GMO fragments gTF1. gTF1 is PCR amplified from the genome of a genetically-modified soybean, MON87705. The arrow indicates successful amplification of the targeted amplicon.

Supplementary Figure 9. PAGE analyses and PNA invasion-mediated endpoint measurements towards products amplified by traditional PCR. PAGE analyses reveal that PCR successfully amplifies (**a**) 1 ng (25 pM) to 0.1pg (2.5 fM) of target gTF1 and (**b**) 50 ng (3.66 fM) GMO genomic DNA diluted without background. In the presence of interfering DNA and BSA as background, PCR fails to produce detectable amplicons (**c**) below 25 fM gTF1 and (**d**) 3.66 fM GMO genomic DNA as templates. (**e**) Weak fluorescent signals are observed by the PNA invasion-mediated method from the PCR products containing 25 and 2.5 fM GMO fragment gTF1 as templates. (**f**) No fluorescence variations are observed from the PCR products using GMO genomic DNA as templates. (Fluorescence signals of CRISDA products are adopted from Fig. 4b and 4c) $n = 4$ technical replicates, two-tailed Student's *t* test, bars represent mean \pm s.d.

Supplementary Figure 10. CRISDA cannot discriminate single-nucleotide mutations at the $+3 \sim +5$ **sites in the seed sequence.** (a) Schematic of wild type pTF1 fragment and various mutants bearing single-nucleotide mutations at the $+3 \sim +5$ sites in the seed sequences. WT: wild type, M3: +3 mutant, M4: +4 mutant and M5: +5 mutant. (**b**) PAGE analyses showing that CRISDA cannot discriminate pTF1 fragments with single-nucleotide mutations at the $+3 \sim +5$ sites in the seed sequence.

Supplementary Figure 11. PAGE analyses showing that CRISDA discriminates hTF2 fragments with single-nucleotide mutations at the rs3803662 site.

Supplementary Figure 12. Site-specific biotin labeling of S3C-dCas9. (**a**) To construct a dCas9 protein with single cysteine at the N-terminus, the 3rd Serine in Cas9 from pET-28a/Cas9-Cys plasmid (Addgene: Plasmid #53261) is mutated to Cysteine (S3C) and other Cysteines are mutated to Serine (C43S, C125S, C619S, and C1435S). S3C mutation provides a single reaction site for the EZ-link® Maleimide-PEG2-biotin. dCas9 mutations are also indicated in the domain schematic. (**b**) Agarose gel electrophoresis revealing successful biotinylation of active S3C-dCas9.

Supplementary Figure 13. Cas9-mediated enrichment of target DNA enhances sensitivity and reliability of CRISDA. The arrow indicates successful amplification of the targeted amplicon. (reactions performed at the hTF1 concentration of 2.5 aM).

Supplementary Figure 14. Uncropped figures of PAGE gels. Cropped regions are indicated with rectangles as appropriate.

Supplementary Table 1. Sequences of Cas9(H840A)-Cys in plasmid pET28a/Cas9(H840A)-Cys

>Cas9(H840A)-Cys

Labels: Cas9(H840A); 6xHis-Tag; Thrombin Cleavage Site; T7-Tag; H885A mutation of Cas9 HNH catalytic residue; SV40 Nuclear Localization Signal; **HA Epitope**; stop codon (italic) ATGGGCAGCAGC<mark>CATCATCATCATCAC</mark>AGCAGCGGC<mark>CTGGTGCCGCGCGCAGC</mark>CAT<mark>ATGGCTAGCATG</mark>A CTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCATGGACAAGAA GTACAGCATCGGCCTGGACATCGGTACCAACAGCGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCC AGCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGCCACAGCATCAAGAAGAACCTGATCGGCGCCCTGCTGT TCGACAGCGGCGAGACCGCCGAGGCCACCCGCCTGAAGCGCACCGCCCGCCGCCGCTACACCCGCCGCAAGA ACCGCATCTGCTACCTGCAGGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACCGCCT GGAGGAGAGCTTCCTGGTGGAGGAGGACAAGAAGCACGAGCGCCACCCCATCTTCGGCAACATCGTGGACGA GGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGCAAGAAGCTGGTGGACAGCACCGACAAGGCC GACCTGCGCCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGCGGCCACTTCCTGATCGAGGGCGACCT GAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAG AACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGAGCGCCCGCCTGAGCAAGAGCCGCCGCCTGG AGAACCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTTCGGCAACCTGATCGCCCTGAGCCTGGG CCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGACGCCAAGCTGCAGCTGAGCAAGGACACCTAC GACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTCCTGGCCGCCAAGAACC TGAGCGACGCCATCCTGCTGAGCGACATCCTGCGCGTGAACACCGAGATCACCAAGGCCCCCCTGAGCGCCAG CATGATCAAGCGCTACGACGAGCACCACCAGGACCTGACCCTGCTGAAGGCCCTGGTGCGCCAGCAGCTGCCC GAGAAGTACAAGGAGATCTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATCGACGGCGGCGCCAGC CAGGAGGAGTTCTACAAGTTCATCAAGCCCATCCTGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGC TGAACCGCGAGGACCTGCTGCGCAAGCAGCGCACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGG CGAGCTGCACGCCATCCTGCGCCGCCAGGAGGACTTCTACCCCTTCCTGAAGGACAACCGCGAGAAGATCGAG AAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCCCTGGCCCGCGGCAACAGCCGCTTCGCCTGGATGAC CCGCAAGAGCGAGGAGACCATCACCCCCTGGAACTTCGAGGAGGTGGTGGACAAGGGCGCCAGCGCCCAGAG CTTCATCGAGCGCATGACCAACTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTG TACGAGTACTTCACCGTGTACAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGCAAGCCCGCCT TCCTGAGCGGCGAGCAGAAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGCAAGGTGACCGTGAAGC AGCTGAAGGAGGACTACTTCAAGAAGATCGAGTGCTTCGACAGCGTGGAGATCAGCGGCGTGGAGGACCGCTT CAACGCCAGCCTGGGCACCTACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAG AACGAGGACATCCTGGAGGACATCGTGCTGACCCTGACCCTGTTCGAGGACCGCGAGATGATCGAGGAGCGCC TGAAGACCTACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAAGCGCCGCCGCTACACCGGCTGGGG CCGCCTGAGCCGCAAGCTTATCAACGGCATCCGCGACAAGCAGAGCGGCAAGACCATCCTGGACTTCCTGAAG AGCGACGGCTTCGCCAACCGCAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTCAAGGAGGACATCC AGAAGGCCCAGGTGAGCGGCCAGGGCGACAGCCTGCACGAGCACATCGCCAACCTGGCCGGCAGCCCCGCCA TCAAGAAGGGCATCCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGCCACAAGCCCG AGAACATCGTGATCGAGATGGCCCGCGAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGCGAGCGCA TGAAGCGCATCGAGGAGGGCATCAAGGAGCTGGGCAGCCAGATCCTGAAGGAGCACCCCGTGGAGAACACCC AGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGCGACATGTACGTGGACCAGGAGCTGGA CATCAACCGCCTGAGCGACTACGACGTGGACGCCATCGTGCCCCAGAGCTTCCTGAAGGACGACAGCATCGAC AACAAGGTGCTGACCCGCAGCGACAAGAACCGCGGCAAGAGCGACAACGTGCCCAGCGAGGAGGTGGTGAAG AAGATGAAGAACTACTGGCGCCAGCTGCTGAACGCCAAGCTGATCACCCAGCGCAAGTTCGACAACCTGACCA AGGCCGAGCGCGGCGGCCTGAGCGAGCTGGACAAGGCCGGCTTCATCAAGCGCCAGCTGGTGGAGACCCGCC AGATCACCAAGCACGTGGCCCAGATCCTGGACAGCCGCATGAACACCAAGTACGACGAGAACGACAAGCTGA TCCGCGAGGTGAAGGTGATCACCCTGAAGAGCAAGCTGGTGAGCGACTTCCGCAAGGACTTCCAGTTCTACAA GGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCCGTGGTGGGCACCGCCCTGATC AAGAAGTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGCAAGATGATCG CCAAGAGCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTCTTCAA GACCGAGATCACCCTGGCCAACGGCGAGATCCGCAAGCGCCCCCTGATCGAGACCAACGGCGAGACCGGCGA GATCGTGTGGGACAAGGGCCGCGACTTCGCCACCGTGCGCAAGGTGCTGAGCATGCCCCAGGTGAACATCGTG AAGAAGACCGAGGTGCAGACCGGCGGCTTCAGCAAGGAGAGCATCCTGCCCAAGCGCAACAGCGACAAGCTG ATCGCCCGCAAGAAGGACTGGGACCCCAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTACAGCGTGC TGGTGGTGGCCAAGGTGGAGAAGGGCAAGAGCAAGAAGCTGAAGAGCGTGAAGGAGCTGCTGGGCATCACCA TCATGGAGCGCAGCAGCTTCGAGAAGAACCCCATCGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTGAAGA AGGACCTGATCATCAAGCTGCCCAAGTACAGCCTGTTCGAGCTGGAGAACGGCCGCAAGCGCATGCTGGCCAG CGCCGGCGAGCTGCAGAAGGGCAACGAGCTGGCCCTGCCCAGCAAGTACGTGAACTTCCTGTACCTGGCCAGC CACTACGAGAAGCTGAAGGGCAGCCCCGAGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCAC TACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCAGCAAGCGCGTGATCCTGGCCGACGCCAACCTGGACA AGGTGCTGAGCGCCTACAACAAGCACCGCGACAAGCCCATCCGCGAGCAGGCCGAGAACATCATCCACCTGTT CACCCTGACCAACCTGGGCGCCCCCGCCGCCTTCAAGTACTTCGACACCACCATCGACCGCAAGCGCTACACC AGCACCAAGGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGTCTGTACGAGACCCGCATCGACC TGAGCCAGCTGGGCGGCGACGGCGGCTCCGGACCTCCAAAGAAAAAGAGAAAAGTATACCCCTACGACGTGC GACTACGCCTGT*TAA*

Supplementary Table 2. Sequences of S3C-dCas9 in plasmid pET28a/S3C-dCas9

>S3C-dCas9

Labels: Serine to Cysteine Mutation (S3C); Cas9(H840); 6xHis-Tag; Thrombin Cleavage Site; T7-Tag; D55A (D10A) mutation and H885A (H840A) mutation of Cas9 RuvC and HNH catalytic residue; SV40 Nuclear Localization Signal; HA Epitope; Cysteine to Serine mutation (bold); stop codon (italic) ATGGGC<mark>TGC</mark>AGC<mark>CATCATCATCATCACAG</mark>AGCAGCGGCCTGGTGCCGCGGGCAGCCATATGGCTAGCAT GACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCT**AGC**GGCCGCATGGAC AAGAAGTACAGCATCGGCCTGGCCATCGGTACCAACAGCGTGGGCTGGGCCGTGATCACCGACGAGTACAA GGTGCCCAGCAAGAAGTTCAAGGTGCTGGGCAACACCGACCGCCACAGCATCAAGAAGAACCTGATCGGCG CCCTGCTGTTCGACAGCGGCGAGACCGCCGAGGCCACCCGCCTGAAGCGCACCGCCCGCCGCCGCTACAC CCGCCGCAAGAACCGCATC**AGC**TACCTGCAGGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCT TCTTCCACCGCCTGGAGGAGAGCTTCCTGGTGGAGGAGGACAAGAAGCACGAGCGCCACCCCATCTTCGGC AACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGCGCAAGAAGCTGGTGGA CAGCACCGACAAGGCCGACCTGCGCCTGATCTACCTGGCCCTGGCCCACATGATCAAGTTCCGCGGCCACT TCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACC TACAACCAGCTGTTCGAGGAGAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGAGCGCCC GCCTGAGCAAGAGCCGCCGCCTGGAGAACCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAACGGCCTGTT CGGCAACCTGATCGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGACG CCAAGCTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCA GTACGCCGACCTGTTCCTGGCCGCCAAGAACCTGAGCGACGCCATCCTGCTGAGCGACATCCTGCGCGTGA ACACCGAGATCACCAAGGCCCCCCTGAGCGCCAGCATGATCAAGCGCTACGACGAGCACCACCAGGACCTG ACCCTGCTGAAGGCCCTGGTGCGCCAGCAGCTGCCCGAGAAGTACAAGGAGATCTTCTTCGACCAGAGCAA GAACGGCTACGCCGGCTACATCGACGGCGGCGCCAGCCAGGAGGAGTTCTACAAGTTCATCAAGCCCATCC TGGAGAAGATGGACGGCACCGAGGAGCTGCTGGTGAAGCTGAACCGCGAGGACCTGCTGCGCAAGCAGCG CACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGCGAGCTGCACGCCATCCTGCGCCGCCAG GAGGACTTCTACCCCTTCCTGAAGGACAACCGCGAGAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTAC TACGTGGGCCCCCTGGCCCGCGGCAACAGCCGCTTCGCCTGGATGACCCGCAAGAGCGAGGAGACCATCA CCCCCTGGAACTTCGAGGAGGTGGTGGACAAGGGCGCCAGCGCCCAGAGCTTCATCGAGCGCATGACCAA CTTCGACAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTA CAACGAGCTGACCAAGGTGAAGTACGTGACCGAGGGCATGCGCAAGCCCGCCTTCCTGAGCGGCGAGCAG AAGAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGCAAGGTGACCGTGAAGCAGCTGAAGGAGGACTA CTTCAAGAAGATCGAG**AGC**TTCGACAGCGTGGAGATCAGCGGCGTGGAGGACCGCTTCAACGCCAGCCTG GGCACCTACCACGACCTGCTGAAGATCATCAAGGACAAGGACTTCCTGGACAACGAGGAGAACGAGGACAT CCTGGAGGACATCGTGCTGACCCTGACCCTGTTCGAGGACCGCGAGATGATCGAGGAGCGCCTGAAGACCT ACGCCCACCTGTTCGACGACAAGGTGATGAAGCAGCTGAAGCGCCGCCGCTACACCGGCTGGGGCCGCCT GAGCCGCAAGCTTATCAACGGCATCCGCGACAAGCAGAGCGGCAAGACCATCCTGGACTTCCTGAAGAGCG ACGGCTTCGCCAACCGCAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTCAAGGAGGACATCCAG AAGGCCCAGGTGAGCGGCCAGGGCGACAGCCTGCACGAGCACATCGCCAACCTGGCCGGCAGCCCCGCC ATCAAGAAGGGCATCCTGCAGACCGTGAAGGTGGTGGACGAGCTGGTGAAGGTGATGGGCCGCCACAAGC CCGAGAACATCGTGATCGAGATGGCCCGCGAGAACCAGACCACCCAGAAGGGCCAGAAGAACAGCCGCGA GCGCATGAAGCGCATCGAGGAGGGCATCAAGGAGCTGGGCAGCCAGATCCTGAAGGAGCACCCCGTGGAG AACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAACGGCCGCGACATGTACGTGGACCA GGAGCTGGACATCAACCGCCTGAGCGACTACGACGTGGACGCACATCGTGCCCCAGAGCTTCCTGAAGGAC GACAGCATCGACAACAAGGTGCTGACCCGCAGCGACAAGAACCGCGGCAAGAGCGACAACGTGCCCAGCG AGGAGGTGGTGAAGAAGATGAAGAACTACTGGCGCCAGCTGCTGAACGCCAAGCTGATCACCCAGCGCAAG TTCGACAACCTGACCAAGGCCGAGCGCGGCGGCCTGAGCGAGCTGGACAAGGCCGGCTTCATCAAGCGCC AGCTGGTGGAGACCCGCCAGATCACCAAGCACGTGGCCCAGATCCTGGACAGCCGCATGAACACCAAGTAC GACGAGAACGACAAGCTGATCCGCGAGGTGAAGGTGATCACCCTGAAGAGCAAGCTGGTGAGCGACTTCCG CAAGGACTTCCAGTTCTACAAGGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACG CCGTGGTGGGCACCGCCCTGATCAAGAAGTACCCCAAGCTGGAGAGCGAGTTCGTGTACGGCGACTACAAG GTGTACGACGTGCGCAAGATGATCGCCAAGAGCGAGCAGGAGATCGGCAAGGCCACCGCCAAGTACTTCTT CTACAGCAACATCATGAACTTCTTCAAGACCGAGATCACCCTGGCCAACGGCGAGATCCGCAAGCGCCCCCT GATCGAGACCAACGGCGAGACCGGCGAGATCGTGTGGGACAAGGGCCGCGACTTCGCCACCGTGCGCAAG GTGCTGAGCATGCCCCAGGTGAACATCGTGAAGAAGACCGAGGTGCAGACCGGCGGCTTCAGCAAGGAGA GCATCCTGCCCAAGCGCAACAGCGACAAGCTGATCGCCCGCAAGAAGGACTGGGACCCCAAGAAGTACGG CGGCTTCGACAGCCCCACCGTGGCCTACAGCGTGCTGGTGGTGGCCAAGGTGGAGAAGGGCAAGAGCAAG AAGCTGAAGAGCGTGAAGGAGCTGCTGGGCATCACCATCATGGAGCGCAGCAGCTTCGAGAAGAACCCCAT CGACTTCCTGGAGGCCAAGGGCTACAAGGAGGTGAAGAAGGACCTGATCATCAAGCTGCCCAAGTACAGCC TGTTCGAGCTGGAGAACGGCCGCAAGCGCATGCTGGCCAGCGCCGGCGAGCTGCAGAAGGGCAACGAGCT GGCCCTGCCCAGCAAGTACGTGAACTTCCTGTACCTGGCCAGCCACTACGAGAAGCTGAAGGGCAGCCCCG AGGACAACGAGCAGAAGCAGCTGTTCGTGGAGCAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATC AGCGAGTTCAGCAAGCGCGTGATCCTGGCCGACGCCAACCTGGACAAGGTGCTGAGCGCCTACAACAAGCA CCGCGACAAGCCCATCCGCGAGCAGGCCGAGAACATCATCCACCTGTTCACCCTGACCAACCTGGGCGCCC CCGCCGCCTTCAAGTACTTCGACACCACCATCGACCGCAAGCGCTACACCAGCACCAAGGAGGTGCTGGAC GCCACCCTGATCCACCAGAGCATCACCGGTCTGTACGAGACCCGCATCGACCTGAGCCAGCTGGGCGGCG ACGGCGGCTCCGGACCTCCAAAGAAAAAGAGAAAAGTATACCCCTACGACGTGCCCGACTACGCC**AGT***TAA*

Supplementary Table 3. Sequences of oligonucleotides used to study the mechanism of CRISDA

Supplementary Table 4. Sequences of DNA oligonucleotides for generating CRISDA templates in study

Supplementary Table 5. Sequences of DNA oligonucleotides for constructing different pDR274-sgRNA expression plasmids

Supplementary Table 6. Sequences of initiating primer (IP) pairs to trigger exponential amplification in CRISDA reactions

Supplementary Table 7. Sequences of PCR primer pair to compare the performance between CRISDA and PCR

Supplementary Table 8. Sequences of oligonucleotides for generating pGL3-100- TargeWT vector and its mutants

Supplementary Table 9. PNAs used in the study for endpoint measurements

Supplementary Table 10. Summary of sgRNAs applied to detect regions in the human genome in this study

* sequences are analyzed by an online tool, CRISPR Design (V1, Zhang's Lab, MIT, 2013), at[: http://crispr.mit.edu/.](http://crispr.mit.edu/)

Supplementary Table 11. The GC-content and melting temperature of the middle region in IP primers used in this study.

